Financial Daily from THE HINDU group of publications
Monday, November 7, 2005
|
Financial Daily from THE HINDU group of publications Monday, November 7, 2005 |
|
|
|
|
|
News Update as at 17.00 hrs (IST)
Corporate NEW DELHI: Aurobindo Pharma Ltd on Monday said that it had received tentative approval from the US Food and Drug Administration for its oral solution of the HIV/AIDS drug Lamivudine. The tentative approval is for 10 mg/ml of oral solution of Lamivudine, the company said in a statement. It said Lamivudine oral solution of 10 mg/ml is the first generic version approval of Epivir oral solution of GlaxosmithKline. Lamivudine is an antiviral drug called a nucleoside reverse transcriptase inhibitor or NRTI, which is used to treat human immunodeficiency virus (HIV) used in combination with other medicines. It is also used to treat infections due to hepatitis B. This approval by US FDA once again makes the company to qualify under the President's emergency plan for AIDS relief (PEPFAR) program, it said. Apart from this approval, Aurobindo already has seven product approvals under PEPFAR programme. - PTI
Prev: Welspun-Gujarat bags Rs 310.5 cr order from Algeria Business Line | NUS Index | |
In Focus Indian Aviation: Sky is the limit Stock splits India Inc's bonus bonanza Dabhol power regenerated Sethusamudram Canal Project India Inc's overseas acquisition
In Depth Gender Justice Simple Economics Tax Talk
|
|
The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription Group Sites: The Hindu | Business Line | The Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |
Copyright © 2004, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line
|